ijms-logo

Journal Browser

Journal Browser

New Insights into Chemotherapeutic Agents in Cancer Treatment

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".

Deadline for manuscript submissions: 30 September 2025 | Viewed by 585

Special Issue Editor


E-Mail Website
Guest Editor
Department of Clinical Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
Interests: chemotherapy; molecular mechanisms; signal transduction; apoptosis; drug; resistance; biomarkers; DNA damage; targeted therapy; cancer pathways; nanoparticles; nanomedicine; epigenetics

Special Issue Information

Dear Colleagues,

We are delighted to announce the new Special Issue of the International Journal of Molecular Sciences, entitled “New Insights into Chemotherapeutic Agents in Cancer Treatment”. This issue seeks to highlight innovative research that advances our understanding of chemotherapeutic agents, exploring their mechanisms, efficacy, toxicities, and integration into progressive oncological practices.

The focus of this Special Issue includes the development of novel chemotherapeutic agents, mechanisms underlying drug action and resistance, innovative delivery systems, novel approaches into diminishing toxicity regarding cancer treatment, and the role of molecular and genetic biomarkers in optimizing therapeutic strategies. Contributions that address challenges such as overcoming drug resistance, minimizing toxicity, and enhancing patient-specific treatment outcomes are more than welcome.

This Special Issue provides a platform for multidisciplinary collaboration and aims to shape the future of cancer therapeutics. We invite you to share your valuable insights and findings with the scientific community as we collectively work towards improving the landscape of cancer care.

Dr. Eleni Stamoula
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chemotherapy
  • molecular mechanisms
  • signal transduction
  • apoptosis
  • drug resistance
  • biomarkers
  • DNA damage
  • targeted therapy
  • cancer pathways
  • nanoparticles
  • nanomedicine
  • epigenetics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

29 pages, 5545 KiB  
Article
Elacridar Inhibits BCRP Protein Activity in 2D and 3D Cell Culture Models of Ovarian Cancer and Re-Sensitizes Cells to Cytotoxic Drugs
by Piotr Stasiak, Justyna Sopel, Artur Płóciennik, Oliwia Musielak, Julia Maria Lipowicz, Agnieszka Anna Rawłuszko-Wieczorek, Karolina Sterzyńska, Jan Korbecki and Radosław Januchowski
Int. J. Mol. Sci. 2025, 26(12), 5800; https://doi.org/10.3390/ijms26125800 - 17 Jun 2025
Viewed by 452
Abstract
Chemotherapy resistance is a major obstacle in the treatment of ovarian cancer, often resulting in disease recurrence and poor prognosis for patients. A key contributor to this resistance is the overexpression of ATP-binding cassette (ABC) transporters, including breast cancer resistance protein (BCRP/ABCG2), which [...] Read more.
Chemotherapy resistance is a major obstacle in the treatment of ovarian cancer, often resulting in disease recurrence and poor prognosis for patients. A key contributor to this resistance is the overexpression of ATP-binding cassette (ABC) transporters, including breast cancer resistance protein (BCRP/ABCG2), which actively effluxes chemotherapeutic agents such as topotecan (TOP) or mitoxantrone (MIT), limiting their intracellular accumulation and efficacy. This study investigated the potential of elacridar (GG918), a potent dual P-gp and BCRP inhibitor, to overcome drug resistance in ovarian cancer cell lines. Both TOP-sensitive and TOP-resistant ovarian cancer cells were grown in two-dimensional (2D) monolayers and three-dimensional (3D) spheroid models to better mimic the tumor microenvironment. The expression of the ABCG2 gene was quantified via qPCR and BCRP protein levels were assessed by western blotting and immunofluorescence. Drug response was evaluated using MTT viability assays, while BCRP transporter activity was examined using flow cytometry and microscopic assessment of the intracellular retention of BCRP fluorescent substrates (Hoechst 33342 and MIT). In both 2D and 3D cultures, elacridar effectively inhibited BCRP function and significantly enhanced sensitivity to TOP. These findings suggest that elacridar can inhibit BCRP-mediated drug resistance in ovarian cancer cell models. Full article
(This article belongs to the Special Issue New Insights into Chemotherapeutic Agents in Cancer Treatment)
Show Figures

Figure 1

Back to TopTop